KIR3DL2 binding agents
US11858990B2 · kind B2 · utility
2Cited by
10References
7Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 28, 2020 |
| Grant date | Jan 2, 2024 |
| Priority date | — |
| Expiry date | Jun 12, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/7095
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to methods for the treatment of cancer and inflammatory disease using antibodies (e.g. monoclonal antibodies), antibody fragments, and derivatives thereof that specifically bind KIR3DL2. The invention also relates to antibodies, cells producing such antibodies; methods of making such antibodies; fragments, variants, and derivatives of the antibodies; pharmaceutical compositions comprising the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.